Novel dual action anti-neoplastic drugs
Article Sidebar
Main Article Content
Abstract
A novel drug structure (a Markush structure) is presented including molecules that can be effective as dual action drugs namely as inhibitors of epidermal growth factor kinase domain as well as having anti-angiogenic activity. The novel Markush structure includes molecules that might have dual anti-neoplastic activity leading to the development of a novel effective cancer drug for treating e.g., pancreatic cancer.
Article Details
References
Rahib et al., "Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States", Cancer Res; 74(11); 2913–21, 2014.
Roth et al., "Recent advances in the treatment of pancreatic cancer", F1000 Research Website, 2020.
Elaileh et al., "Promising new treatments for pancreatic cancer in the era of targeted and immune therapies", Amer. J. Cancer Res. 9(9): 1871–1888, 2019.
Tanase et al., "Cancer stem cells – Involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics", World J.Gastroenterol, 20 (31), 10790-10801, 2014.
Von Hoff et at., "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", The New England Journal of Medicine 369, 1691-1703, 2013.
Abrams et al., "Recent advances in in pancreatic cancer updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology", Therap Adv Gastroenterol. 9(2): 141–151, 2016.
Schober et al., "New advances in the treatment of metastatic pancreatic cancer", Digestion 92, 175-184, 2015.
Martin et al., "VEGF remains an interesting target in advanced pancreatic cancer (APCA): results of multi-institutional phase II study of bevacizumab, gemcitabine, and infusoinal 5-flurouracil in patients with APCA", Annals of Oncology 23, 2812-2820, 2012.
Stamos et al., "Structure of the EGFR kinase domain and in complex with a 4-aniniloquinazoline inhibitor", Journal of biological chemistry, Vol. 277, No. 48, 46265-46272, 2002.
Komba et al., "Degradation of fucoxanthin to elucidate the relationship between the fucoxanthin molecular structure and its anti-proliferative effect on Caco-2 cells”, Mar. Drugs, 2018, 16, 275.
Wang et al., "In vivo induction of apoptosis by fucoxanthin", Mar. Drugs, 2012, 10(9), 2055-2068.
Scott et al., "Therapeutic approaches to RAS mutations", Cancer J., 22(3) 165-174, 2016.